Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2026-06-26 @ 4:51 AM
Study NCT ID:
NCT03000569
Status:
COMPLETED
Last Update Posted:
2023-11-29
First Post:
2016-11-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}], 'ancestors': [{'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000634505', 'term': 'zuranolone'}, {'id': 'D007980', 'term': 'Levodopa'}], 'ancestors': [{'id': 'D004295', 'term': 'Dihydroxyphenylalanine'}, {'id': 'D002395', 'term': 'Catecholamines'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D002396', 'term': 'Catechols'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D010649', 'term': 'Phenylalanine'}, {'id': 'D024322', 'term': 'Amino Acids, Aromatic'}, {'id': 'D000598', 'term': 'Amino Acids, Cyclic'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D014443', 'term': 'Tyrosine'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@biogen.com', 'phone': '866-633-4636', 'title': 'US Biogen Clinical Trial Center', 'organization': 'Biogen'}, 'certainAgreement': {'otherDetails': "Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Part A: Up to 14 days; Part B: Up to 14 days', 'description': 'The safety population included all participants who were administered study drug \\[SAGE-217 or levodopa (Part A); or SAGE-217 or antiparkinsonian agent(s) (Part B)\\]. Number of participants at risk is number of participants in the safety population that remained in the study during each period.', 'eventGroups': [{'id': 'EG000', 'title': 'Part A: Antiparkinsonian Agent(s) Day 1 to Day 3', 'description': 'Participants received levodopa as antiparkinsonian agents at the normally prescribed dosing schedule, orally for Days 1 to 3.', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 4, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Part A: SAGE-217 Day 4 to Day 7', 'description': 'Participants received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. If the initial dose was not tolerated, doses could be reduced to 10 or 20 mg per day.', 'otherNumAtRisk': 14, 'deathsNumAtRisk': 14, 'otherNumAffected': 14, 'seriousNumAtRisk': 14, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Part A: Follow-up', 'description': 'Participants resumed levodopa as antiparkinsonian agents at the normally prescribed dosing schedule for Days 8 to 14.', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 2, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Part B: SAGE-217 Dose 1 to Dose 7', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.', 'otherNumAtRisk': 14, 'deathsNumAtRisk': 14, 'otherNumAffected': 8, 'seriousNumAtRisk': 14, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Part B: Follow-up', 'description': 'Participants received antiparkinsonian agent(s) at normally prescribed dosing schedule for Days 8 to 14.', 'otherNumAtRisk': 14, 'deathsNumAtRisk': 14, 'otherNumAffected': 0, 'seriousNumAtRisk': 14, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Sedation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Myoclonus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Amnesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Cognitive Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Dyskinesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Migraine with Aura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': "Parkinson's Disease", 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Abdominal Distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Faeces soft', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Haematochezia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Salivary Hypersecretion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Feeling drunk', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Orthostatic Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Photophobia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Lipase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Pain in Extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Limb Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Panic Attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Confusional State', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Hypoxia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}, {'term': 'Dermatitis Contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 14, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (19.1)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Day 1 to Day 3', 'description': 'Participants received levodopa as antiparkinsonian agents at the normally prescribed dosing schedule, orally for Days 1 to 3.'}, {'id': 'OG001', 'title': 'Part A: SAGE-217 Day 4 to Day 7', 'description': 'Participants received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. If the initial dose was not tolerated, doses could be reduced to 10 or 20 mg per day.'}, {'id': 'OG002', 'title': 'Part A: Follow-up', 'description': 'Participants resumed levodopa as antiparkinsonian agents at the normally prescribed dosing schedule for Days 8 to 14.'}], 'classes': [{'categories': [{'measurements': [{'value': '26.7', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '13.3', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 to Day 14', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Overall number of participants analyzed = Number of participants in the safety population that remained in the study during each period.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With TEAEs, Graded by Severity - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Day 1 to Day 3', 'description': 'Participants received levodopa as antiparkinsonian agents at the normally prescribed dosing schedule, orally for Days 1 to 3.'}, {'id': 'OG001', 'title': 'Part A: SAGE-217 Day 4 to Day 7', 'description': 'Participants received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. If the initial dose was not tolerated, doses could be reduced to 10 or 20 mg per day.'}, {'id': 'OG002', 'title': 'Part A: Follow-up', 'description': 'Participants resumed levodopa as antiparkinsonian agents at the normally prescribed dosing schedule for Days 8 to 14.'}], 'classes': [{'title': 'Mild', 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '6.7', 'groupId': 'OG002'}]}]}, {'title': 'Moderate', 'categories': [{'measurements': [{'value': '6.7', 'groupId': 'OG000'}, {'value': '85.7', 'groupId': 'OG001'}, {'value': '6.7', 'groupId': 'OG002'}]}]}, {'title': 'Severe', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '14.3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 to Day 14', 'description': 'Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with an inability to perform normal activities). The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Overall number of participants analyzed = Number of participants in the safety population that remained in the study during each period.'}, {'type': 'PRIMARY', 'title': 'Change From Baseline (CFB) in Basophils - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.051', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.043', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.036', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.038', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.041', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells per liter (10^9 cells/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Basophils to Leukocytes Ratio [Percentage (%)] - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '0.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.35', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as International System (SI) unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Eosinophils - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.17', 'spread': '0.098', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.083', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.051', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.073', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.053', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Eosinophils to Leukocytes Ratio (%) - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.9', 'spread': '1.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '1.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.11', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Erythrocytes - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.63', 'spread': '0.475', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.266', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.224', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.265', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.226', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^12 cells per liter (10^12 cells/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Hematocrit - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.434', 'spread': '0.0444', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.003', 'spread': '0.0264', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.004', 'spread': '0.0247', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.002', 'spread': '0.0285', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.013', 'spread': '0.0222', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'liters per liter (L/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Hemoglobin - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '142.0', 'spread': '13.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '7.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '7.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '8.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.9', 'spread': '5.82', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'grams per liter (g/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Leukocytes - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.04', 'spread': '1.139', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.24', 'spread': '1.085', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.15', 'spread': '0.536', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.874', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.30', 'spread': '0.941', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Lymphocytes - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14..'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.70', 'spread': '0.318', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.289', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.352', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.286', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.17', 'spread': '0.183', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Lymphocytes to Leukocytes Ratio (%) - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '28.3', 'spread': '4.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '4.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '5.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '4.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '4.22', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Monocytes - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.36', 'spread': '0.112', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.125', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.076', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.101', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.064', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Monocytes to Leukocytes Ratio (%) - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.1', 'spread': '1.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.48', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.22', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Neutrophils- Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.79', 'spread': '0.861', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.27', 'spread': '0.848', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.599', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.17', 'spread': '0.680', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.44', 'spread': '0.861', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Neutrophils to Leukocytes Ratio (%) - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '62.5', 'spread': '4.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '4.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '5.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '4.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '4.64', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Platelets - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '218.9', 'spread': '62.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.6', 'spread': '27.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.8', 'spread': '33.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7.8', 'spread': '21.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '11.5', 'spread': '36.42', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Reticulocytes - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '64.6', 'spread': '20.36', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '17.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '19.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '20.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '14.10', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Reticulocytes to Erythrocytes Ratio (%) - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.41', 'spread': '0.442', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.349', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.409', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.424', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.315', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Activated Partial Thromboplastin Time - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '24.80', 'groupId': 'OG000', 'lowerLimit': '22.9', 'upperLimit': '27.4'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.20', 'groupId': 'OG000', 'lowerLimit': '-1.5', 'upperLimit': '4.0'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.25', 'groupId': 'OG000', 'lowerLimit': '-4.8', 'upperLimit': '2.4'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'groupId': 'OG000', 'lowerLimit': '-1.6', 'upperLimit': '1.4'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.10', 'groupId': 'OG000', 'lowerLimit': '-2.1', 'upperLimit': '4.7'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'seconds (sec)', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Prothrombin International Normalized Ratio - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.04', 'spread': '0.065', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.108', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.065', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.243', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.155', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Prothrombin Time - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '10.70', 'groupId': 'OG000', 'lowerLimit': '10.2', 'upperLimit': '12.4'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '-0.6', 'upperLimit': '2.2'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '-1.2', 'upperLimit': '0.4'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.10', 'groupId': 'OG000', 'lowerLimit': '-0.7', 'upperLimit': '7.5'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'groupId': 'OG000', 'lowerLimit': '-1.2', 'upperLimit': '4.7'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'sec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Alanine Aminotransferase - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '15.8', 'spread': '8.12', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '15.3', 'spread': '11.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '13.9', 'spread': '11.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7.2', 'spread': '13.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.3', 'spread': '9.24', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'units per liter (U/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Albumin - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '43.2', 'spread': '1.70', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '1.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '2.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.35', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Alkaline Phosphatase - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '80.6', 'spread': '14.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '9.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '4.52', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '4.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '8.06', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Aspartate Aminotransferase - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '23.2', 'spread': '7.24', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '6.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '4.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '5.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '5.16', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Bicarbonate - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '22.4', 'spread': '2.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '2.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '2.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '2.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '2.26', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'millimoles per liter (mmol/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Bilirubin - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.082', 'spread': '3.8041', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.029', 'spread': '3.4758', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.949', 'spread': '3.8554', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.545', 'spread': '3.5965', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.543', 'spread': '3.7159', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'micromoles per liter (umol/L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Calcium - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.342', 'spread': '0.0588', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.030', 'spread': '0.0734', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.007', 'spread': '0.0779', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.014', 'spread': '0.0711', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.015', 'spread': '0.0842', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Chloride - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '100.1', 'spread': '2.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '1.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '2.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '2.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.83', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Creatinine - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '73.254', 'spread': '17.7960', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.399', 'spread': '8.6574', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.104', 'spread': '9.4424', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.420', 'spread': '10.9866', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.118', 'spread': '4.6761', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Lipase - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '34.5', 'spread': '10.16', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '16.6', 'spread': '22.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.1', 'spread': '77.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '73.3', 'spread': '222.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '7.67', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Magnesium - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.861', 'spread': '0.0686', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.012', 'spread': '0.0409', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.0457', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.015', 'spread': '0.0617', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.016', 'spread': '0.0618', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Phosphate - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.098', 'spread': '0.1189', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.035', 'spread': '0.1413', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.076', 'spread': '0.1645', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.083', 'spread': '0.1513', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.034', 'spread': '0.1698', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Potassium - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.53', 'spread': '0.326', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.14', 'spread': '0.323', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.309', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.15', 'spread': '0.350', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.446', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Protein - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '69.4', 'spread': '3.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '4.12', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '3.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '3.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '4.33', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Sodium - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '140.0', 'spread': '1.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '2.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '1.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '2.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.85', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Urate - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.337', 'spread': '0.1000', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.005', 'spread': '0.0713', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.010', 'spread': '0.0804', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.014', 'spread': '0.0394', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.014', 'spread': '0.0649', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Urea Nitrogen - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.831', 'spread': '1.3672', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.587', 'spread': '1.4925', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.816', 'spread': '1.4715', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.663', 'spread': '1.5521', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.048', 'spread': '1.3484', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Specific Gravity - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.018', 'spread': '0.0049', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.001', 'spread': '0.0062', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.0039', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.002', 'spread': '0.0059', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and potential of hydrogen (pH). Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in pH - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.87', 'spread': '0.915', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.18', 'spread': '0.973', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.881', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.884', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'pH', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Temperature - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '36.61', 'spread': '0.228', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.180', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.205', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.236', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.227', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.285', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.235', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.412', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.319', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.296', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.346', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.316', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.348', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.323', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.279', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.274', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.283', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.380', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.380', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.365', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.409', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.305', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.277', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.272', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.331', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.363', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.276', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.422', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.372', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.176', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.208', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.175', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.387', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.236', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.236', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.230', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.336', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.333', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.12', 'spread': '0.185', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.233', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.187', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.287', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.16', 'spread': '0.360', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.17', 'spread': '0.272', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.449', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.16', 'spread': '0.310', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.421', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.400', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.273', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.383', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.359', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.306', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.322', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.322', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.358', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.260', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.329', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.697', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.434', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.434', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.302', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.16', 'spread': '0.282', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.16', 'spread': '0.407', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.16', 'spread': '0.310', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.332', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.252', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.208', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.145', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.235', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.363', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '0.224', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.301', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'degrees Celsius (degrees C)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Heart Rate - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '66.6', 'spread': '11.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '5.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '6.76', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '5.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '6.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '7.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '7.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.5', 'spread': '6.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '7.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '5.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '6.80', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '7.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.9', 'spread': '8.10', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '10.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '5.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '7.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdos', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '7.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.9', 'spread': '8.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '7.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '7.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '9.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.7', 'spread': '6.67', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '9.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '7.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '6.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '7.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.9', 'spread': '5.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.6', 'spread': '9.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '8.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.9', 'spread': '7.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '5.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '6.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '8.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.4', 'spread': '10.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '6.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.7', 'spread': '8.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '7.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.1', 'spread': '9.70', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.2', 'spread': '6.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.6', 'spread': '7.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '8.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '6.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.4', 'spread': '9.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.4', 'spread': '8.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '11.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7.6', 'spread': '11.24', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.2', 'spread': '9.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.4', 'spread': '9.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.6', 'spread': '7.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '9.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.6', 'spread': '7.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.3', 'spread': '6.53', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.9', 'spread': '7.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.2', 'spread': '7.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.2', 'spread': '10.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.1', 'spread': '10.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.6', 'spread': '11.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.8', 'spread': '10.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.2', 'spread': '9.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.4', 'spread': '10.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.4', 'spread': '11.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.0', 'spread': '8.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.3', 'spread': '6.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.9', 'spread': '12.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.4', 'spread': '7.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.0', 'spread': '8.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.8', 'spread': '4.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '9.5', 'spread': '9.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.7', 'spread': '9.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.6', 'spread': '7.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '6.52', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.1', 'spread': '8.29', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'beats per minute (beats/min)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Respiratory Rate - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '15.9', 'spread': '1.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '2.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '2.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.48', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.70', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '2.32', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '2.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '2.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '2.62', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '2.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.13', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '2.11', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '2.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '2.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '2.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '1.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.70', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.95', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.95', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '2.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '2.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '2.10', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.36', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '2.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '2.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.83', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'breaths per minute (breaths/min)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Supine Systolic Blood Pressure - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '124.5', 'spread': '11.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-6.7', 'spread': '10.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-7.1', 'spread': '11.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '10.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.7', 'spread': '9.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.5', 'spread': '9.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '13.32', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.4', 'spread': '13.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'spread': '12.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '11.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '11.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-7.3', 'spread': '11.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.4', 'spread': '9.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '10.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '10.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '10.95', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.2', 'spread': '15.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.9', 'spread': '8.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.4', 'spread': '9.53', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '10.40', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '8.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '10.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-7.4', 'spread': '14.70', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '12.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.7', 'spread': '14.12', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '12.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '12.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.3', 'spread': '13.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '16.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '10.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.5', 'spread': '10.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.8', 'spread': '9.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-6.6', 'spread': '10.80', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.3', 'spread': '15.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '8.84', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '10.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.2', 'spread': '10.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.1', 'spread': '9.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '14.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '10.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '11.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-8.6', 'spread': '9.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-8.1', 'spread': '11.67', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.8', 'spread': '10.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '9.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '11.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '10.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '11.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '15.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '14.19', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.9', 'spread': '11.67', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-8.6', 'spread': '11.95', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '13.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.1', 'spread': '15.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.6', 'spread': '13.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.4', 'spread': '10.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '12.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '12.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.5', 'spread': '10.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '13.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.9', 'spread': '19.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.9', 'spread': '12.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.4', 'spread': '18.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '13.22', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.1', 'spread': '17.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '14.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '10.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.9', 'spread': '13.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '14.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '18.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '7.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.7', 'spread': '9.50', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'millimeters of mercury (mmHg)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Standing Systolic Blood Pressure - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '124.1', 'spread': '12.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '9.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.7', 'spread': '10.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '11.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '11.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.7', 'spread': '13.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.3', 'spread': '10.22', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7.6', 'spread': '17.85', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.9', 'spread': '10.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.7', 'spread': '9.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '11.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '10.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.4', 'spread': '11.56', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.1', 'spread': '9.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '10.12', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.4', 'spread': '8.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '10.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.6', 'spread': '16.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '11.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.4', 'spread': '10.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '7.84', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.2', 'spread': '8.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.9', 'spread': '11.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.4', 'spread': '13.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-6.2', 'spread': '13.13', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '9.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '10.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '14.56', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '15.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.2', 'spread': '11.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.3', 'spread': '13.32', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '14.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.6', 'spread': '10.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '11.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.7', 'spread': '10.04', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '8.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '9.16', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.3', 'spread': '12.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '10.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '10.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '9.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-9.8', 'spread': '12.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-8.3', 'spread': '10.52', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '14.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '9.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.1', 'spread': '12.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '10.16', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '12.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.3', 'spread': '17.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '15.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '12.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-6.4', 'spread': '10.89', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.5', 'spread': '9.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.5', 'spread': '10.36', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '8.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '9.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.7', 'spread': '12.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '12.13', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.5', 'spread': '13.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '19.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '12.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'spread': '13.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.7', 'spread': '13.19', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-6.0', 'spread': '9.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.9', 'spread': '13.96', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '13.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '10.80', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.6', 'spread': '14.54', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '13.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '11.95', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7.6', 'spread': '9.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '13.14', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Supine Diastolic Blood Pressure - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '77.3', 'spread': '7.19', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.3', 'spread': '6.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.7', 'spread': '5.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '6.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '5.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '9.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '9.04', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '7.89', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '8.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.0', 'spread': '10.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '7.10', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.8', 'spread': '9.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.4', 'spread': '9.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '11.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '7.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '10.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '10.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '7.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.9', 'spread': '8.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.4', 'spread': '7.13', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '7.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.1', 'spread': '8.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '8.11', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.3', 'spread': '9.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.9', 'spread': '13.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.1', 'spread': '8.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '9.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '8.32', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '7.80', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '8.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '7.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.9', 'spread': '6.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '6.48', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '8.19', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '8.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '8.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '7.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '6.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '8.84', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'spread': '7.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.1', 'spread': '8.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.4', 'spread': '7.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '6.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '6.62', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '6.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '8.22', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.4', 'spread': '7.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'spread': '9.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.3', 'spread': '7.84', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '10.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '7.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.7', 'spread': '9.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.7', 'spread': '9.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '8.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '11.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '8.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '8.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '9.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '7.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '10.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.9', 'spread': '6.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.1', 'spread': '7.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.5', 'spread': '9.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.7', 'spread': '10.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.5', 'spread': '9.40', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.8', 'spread': '8.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '10.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '8.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.5', 'spread': '10.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.2', 'spread': '9.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '8.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '7.22', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Standing Diastolic Blood Pressure - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '76.7', 'spread': '10.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '8.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '7.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '7.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.3', 'spread': '5.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '10.54', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.1', 'spread': '7.16', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.6', 'spread': '7.04', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '7.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '7.19', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.0', 'spread': '8.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '7.89', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '12.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '8.53', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '10.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '12.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '10.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.3', 'spread': '6.80', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '5.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '5.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.4', 'spread': '7.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '9.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '6.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '12.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '11.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '9.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '11.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '7.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '9.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '10.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.6', 'spread': '9.11', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '8.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '6.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.6', 'spread': '7.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '7.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '8.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.9', 'spread': '7.88', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.8', 'spread': '11.13', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.9', 'spread': '10.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.8', 'spread': '9.24', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.6', 'spread': '5.84', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '5.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '6.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '6.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.7', 'spread': '6.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '6.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '8.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '9.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '9.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '9.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '8.56', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '7.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '7.10', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '10.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '8.84', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '7.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.3', 'spread': '9.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '9.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.1', 'spread': '8.10', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.8', 'spread': '11.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '8.24', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '8.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'spread': '7.54', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '6.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '9.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '7.85', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.7', 'spread': '6.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '10.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.9', 'spread': '11.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '9.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '7.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '8.06', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Pulse Oximetry- Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '96.9', 'spread': '2.22', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.42', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '2.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.42', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '2.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '2.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '2.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.28', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '1.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.70', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.36', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.28', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.96', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '3.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '2.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.28', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.42', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.76', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '2.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '2.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.36', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.56', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '2.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '2.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '1.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '2.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '2.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '2.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.52', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.84', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '2.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '2.28', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '2.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.76', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.77', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Electrocardiogram (ECG) Mean Heart Rate - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '64.7', 'spread': '11.85', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '6.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '6.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.9', 'spread': '7.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7.1', 'spread': '8.89', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.5', 'spread': '5.53', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.2', 'spread': '5.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '9.0', 'spread': '10.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '4.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.9', 'spread': '7.11', 'groupId': 'OG000'}]}]}, {'title': 'Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.5', 'spread': '5.37', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.9', 'spread': '8.76', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.2', 'spread': '6.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '10.7', 'spread': '6.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '4.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.7', 'spread': '9.32', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'beats/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Aggregate PR Interval - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '158.0', 'groupId': 'OG000', 'lowerLimit': '122', 'upperLimit': '228'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '26'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-9', 'upperLimit': '17'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-20', 'upperLimit': '25'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-8.0', 'groupId': 'OG000', 'lowerLimit': '-26', 'upperLimit': '22'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-18', 'upperLimit': '13'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-6.0', 'groupId': 'OG000', 'lowerLimit': '-24', 'upperLimit': '17'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-32', 'upperLimit': '18'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'groupId': 'OG000', 'lowerLimit': '-18', 'upperLimit': '21'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-5.0', 'groupId': 'OG000', 'lowerLimit': '-25', 'upperLimit': '22'}]}]}, {'title': 'Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-30', 'upperLimit': '15'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-26', 'upperLimit': '14'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'groupId': 'OG000', 'lowerLimit': '-32', 'upperLimit': '19'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-18', 'upperLimit': '20'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'groupId': 'OG000', 'lowerLimit': '-24', 'upperLimit': '20'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-8.0', 'groupId': 'OG000', 'lowerLimit': '-34', 'upperLimit': '86'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'milliseconds (msec)', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Aggregate RR Interval - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '950.0', 'groupId': 'OG000', 'lowerLimit': '684', 'upperLimit': '1226'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-32.5', 'groupId': 'OG000', 'lowerLimit': '-298', 'upperLimit': '190'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-43.5', 'groupId': 'OG000', 'lowerLimit': '-298', 'upperLimit': '285'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-99.0', 'groupId': 'OG000', 'lowerLimit': '-263', 'upperLimit': '98'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-98.5', 'groupId': 'OG000', 'lowerLimit': '-376', 'upperLimit': '252'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-56.0', 'groupId': 'OG000', 'lowerLimit': '-143', 'upperLimit': '211'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-102.0', 'groupId': 'OG000', 'lowerLimit': '-276', 'upperLimit': '-30'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-133.0', 'groupId': 'OG000', 'lowerLimit': '-386', 'upperLimit': '182'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-65.0', 'groupId': 'OG000', 'lowerLimit': '-150', 'upperLimit': '84'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-63.0', 'groupId': 'OG000', 'lowerLimit': '-196', 'upperLimit': '36'}]}]}, {'title': 'Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-113.5', 'groupId': 'OG000', 'lowerLimit': '-228', 'upperLimit': '28'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-76.5', 'groupId': 'OG000', 'lowerLimit': '-420', 'upperLimit': '179'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-104.5', 'groupId': 'OG000', 'lowerLimit': '-226', 'upperLimit': '125'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-120.0', 'groupId': 'OG000', 'lowerLimit': '-344', 'upperLimit': '70'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-10.0', 'groupId': 'OG000', 'lowerLimit': '-118', 'upperLimit': '114'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-86.0', 'groupId': 'OG000', 'lowerLimit': '-189', 'upperLimit': '169'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'milliseconds (msec)', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Aggregate QT Interval - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '406.0', 'groupId': 'OG000', 'lowerLimit': '340', 'upperLimit': '445'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '64'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.5', 'groupId': 'OG000', 'lowerLimit': '-39', 'upperLimit': '39'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-9.0', 'groupId': 'OG000', 'lowerLimit': '-44', 'upperLimit': '66'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-15.5', 'groupId': 'OG000', 'lowerLimit': '-92', 'upperLimit': '84'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-8.5', 'groupId': 'OG000', 'lowerLimit': '-41', 'upperLimit': '22'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-12.0', 'groupId': 'OG000', 'lowerLimit': '-42', 'upperLimit': '24'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-22.0', 'groupId': 'OG000', 'lowerLimit': '-42', 'upperLimit': '18'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-4.5', 'groupId': 'OG000', 'lowerLimit': '-33', 'upperLimit': '30'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-9.0', 'groupId': 'OG000', 'lowerLimit': '-61', 'upperLimit': '9'}]}]}, {'title': 'Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-13.0', 'groupId': 'OG000', 'lowerLimit': '-35', 'upperLimit': '26'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-12.5', 'groupId': 'OG000', 'lowerLimit': '-48', 'upperLimit': '56'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-13.0', 'groupId': 'OG000', 'lowerLimit': '-50', 'upperLimit': '20'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-23.0', 'groupId': 'OG000', 'lowerLimit': '-50', 'upperLimit': '55'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-26', 'upperLimit': '32'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-16.0', 'groupId': 'OG000', 'lowerLimit': '-38', 'upperLimit': '20'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Aggregate QRS Duration - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '88.0', 'groupId': 'OG000', 'lowerLimit': '76', 'upperLimit': '106'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-14', 'upperLimit': '8'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-5', 'upperLimit': '22'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '18'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-20', 'upperLimit': '16'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-18', 'upperLimit': '16'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-14', 'upperLimit': '12'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-6', 'upperLimit': '8'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '15'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'groupId': 'OG000', 'lowerLimit': '-18', 'upperLimit': '12'}]}]}, {'title': 'Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-14', 'upperLimit': '21'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '14'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-22', 'upperLimit': '14'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-12', 'upperLimit': '13'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '18'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.0', 'groupId': 'OG000', 'lowerLimit': '-10', 'upperLimit': '12'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Aggregate QTcF Interval - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '419.0', 'groupId': 'OG000', 'lowerLimit': '386', 'upperLimit': '435'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-21', 'upperLimit': '39'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-32', 'upperLimit': '33'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'groupId': 'OG000', 'lowerLimit': '-29', 'upperLimit': '53'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.5', 'groupId': 'OG000', 'lowerLimit': '-85', 'upperLimit': '50'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'groupId': 'OG000', 'lowerLimit': '-65', 'upperLimit': '28'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-19', 'upperLimit': '31'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-7.0', 'groupId': 'OG000', 'lowerLimit': '-23', 'upperLimit': '26'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.5', 'groupId': 'OG000', 'lowerLimit': '-20', 'upperLimit': '24'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '-38', 'upperLimit': '32'}]}]}, {'title': 'Day 6 (SAGE-217): 12 hours postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'groupId': 'OG000', 'lowerLimit': '-14', 'upperLimit': '34'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '32'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-35', 'upperLimit': '23'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'groupId': 'OG000', 'lowerLimit': '-17', 'upperLimit': '46'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'groupId': 'OG000', 'lowerLimit': '-19', 'upperLimit': '37'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-7.0', 'groupId': 'OG000', 'lowerLimit': '-52', 'upperLimit': '35'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': 'CFB in Stanford Sleepiness Scale (SSS) Score - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '0.56', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.52', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.76', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '0.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 1 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '0.85', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '0.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.22', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '0.96', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '0.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 2 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '0.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.85', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 3 (L/C): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '0.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.2', 'spread': '2.28', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.6', 'spread': '2.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '1.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '1.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 4 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '0.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '1.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '1.42', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '0.96', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '0.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 5 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '1.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 1 Hour Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.6', 'spread': '1.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '1.85', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '2.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '1.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.8', 'spread': '1.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.89', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '0.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 6 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.19', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 1 hour postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '1.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 3 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '1.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.7', 'spread': '1.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 6 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 14 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 7 (SAGE-217): 16 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.62', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.59', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': "The SSS was a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of one to seven, where the lowest score of 'one' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of 'seven' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. A negative change from baseline indicated less sleepiness. A positive change from baseline indicated more sleepiness. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'PRIMARY', 'title': "Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item - Part A", 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Suicidal Ideation: Pre-treatment', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Suicidal Ideation: Post-treatment', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Suicidal Behavior: Pre-treatment', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Suicidal Behavior: Post-treatment', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 to Day 14', 'description': 'The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included "yes" or "no"\' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug (SAGE-217 or levodopa).'}, {'type': 'PRIMARY', 'title': "CFB in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II/III Score - Part B", 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '19.1', 'spread': '3.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-5.4', 'spread': '4.52', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-5.9', 'spread': '5.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-6.5', 'spread': '5.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-6.6', 'spread': '4.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-6.0', 'spread': '4.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-5.9', 'spread': '5.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-8.0', 'spread': '5.53', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-7.4', 'spread': '5.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-7.4', 'spread': '7.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-8.0', 'spread': '5.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-5.2', 'spread': '6.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-8.4', 'spread': '5.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-7.7', 'spread': '4.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-3.7', 'spread': '4.34', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14', 'description': 'The modified MDS-UPDRS included 4 scales, with various subscales. Each item was rated from 0 (normal) to 4 (severe). The scales were Part I: nonmotor experiences of daily living (13 items); Part II: motor experiences of daily living (13 items); Part III: motor examination (33 scores based on 18 items \\[several with right, left or other body distribution scores\\]); and Part IV: motor complications (6 items). The Part II/III tremor score was calculated as the sum of 5 individual tremor item scores from Part II and Part III. The total score range for Part II/III is 0 to 44. Lower scores represent less symptom severity and higher scores represent more symptom severity. Baseline is the last measurement taken before the first dose of study drug. A negative change from baseline indicates an improvement in symptom severity. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.'}, {'type': 'SECONDARY', 'title': 'MDS-UPDRS Part III Total Score - Part A', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}], 'classes': [{'title': 'Day 1 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '25.4', 'spread': '9.34', 'groupId': 'OG000'}]}]}, {'title': 'Day 1 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '30.0', 'spread': '10.53', 'groupId': 'OG000'}]}]}, {'title': 'Day 1 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '34.3', 'spread': '10.83', 'groupId': 'OG000'}]}]}, {'title': 'Day 1 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.1', 'spread': '9.71', 'groupId': 'OG000'}]}]}, {'title': 'Day 2 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '27.1', 'spread': '9.15', 'groupId': 'OG000'}]}]}, {'title': 'Day 2 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '31.1', 'spread': '9.65', 'groupId': 'OG000'}]}]}, {'title': 'Day 2 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.1', 'spread': '11.37', 'groupId': 'OG000'}]}]}, {'title': 'Day 2 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '36.1', 'spread': '11.07', 'groupId': 'OG000'}]}]}, {'title': 'Day 3 (L/C): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '26.5', 'spread': '10.95', 'groupId': 'OG000'}]}]}, {'title': 'Day 3 (L/C): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '29.0', 'spread': '10.95', 'groupId': 'OG000'}]}]}, {'title': 'Day 3 (L/C): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.2', 'spread': '10.76', 'groupId': 'OG000'}]}]}, {'title': 'Day 3 (L/C): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '36.2', 'spread': '11.29', 'groupId': 'OG000'}]}]}, {'title': 'Day 4 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.7', 'spread': '14.57', 'groupId': 'OG000'}]}]}, {'title': 'Day 4 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '30.9', 'spread': '12.84', 'groupId': 'OG000'}]}]}, {'title': 'Day 4 (SAGE-217):8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '33.4', 'spread': '11.65', 'groupId': 'OG000'}]}]}, {'title': 'Day 4 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '33.3', 'spread': '13.19', 'groupId': 'OG000'}]}]}, {'title': 'Day 5 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '33.8', 'spread': '12.76', 'groupId': 'OG000'}]}]}, {'title': 'Day 5 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '32.4', 'spread': '12.69', 'groupId': 'OG000'}]}]}, {'title': 'Day 5 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '30.9', 'spread': '12.02', 'groupId': 'OG000'}]}]}, {'title': 'Day 5 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '33.0', 'spread': '12.15', 'groupId': 'OG000'}]}]}, {'title': 'Day 6 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '31.5', 'spread': '11.97', 'groupId': 'OG000'}]}]}, {'title': 'Day 6 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '31.8', 'spread': '9.66', 'groupId': 'OG000'}]}]}, {'title': 'Day 6 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '32.7', 'spread': '12.81', 'groupId': 'OG000'}]}]}, {'title': 'Day 6 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '34.5', 'spread': '11.19', 'groupId': 'OG000'}]}]}, {'title': 'Day 7 (SAGE-217): 2 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '36.4', 'spread': '12.55', 'groupId': 'OG000'}]}]}, {'title': 'Day 7 (SAGE-217): 4 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.8', 'spread': '11.92', 'groupId': 'OG000'}]}]}, {'title': 'Day 7 (SAGE-217): 8 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '36.0', 'spread': '11.73', 'groupId': 'OG000'}]}]}, {'title': 'Day 7 (SAGE-217): 12 Hours Postdose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.6', 'spread': '11.03', 'groupId': 'OG000'}]}]}, {'title': 'Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '35.4', 'spread': '10.54', 'groupId': 'OG000'}]}]}, {'title': 'Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '30.2', 'spread': '13.00', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 1 to 7 (2, 4, 8, and 12 hours postdose), Day 8 and Day 14', 'description': 'Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores indicate less symptom severity. The analysis was performed in participants included in Part A of the study.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in the MDS-UPDRS Part III Total Score - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '52.4', 'spread': '12.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-8.4', 'spread': '8.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-10.8', 'spread': '9.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-11.6', 'spread': '12.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-13.5', 'spread': '7.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-12.4', 'spread': '10.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-10.9', 'spread': '9.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-14.3', 'spread': '12.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-14.8', 'spread': '10.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-14.5', 'spread': '15.52', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-18.1', 'spread': '10.10', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-14.8', 'spread': '11.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-19.5', 'spread': '9.30', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-18.6', 'spread': '9.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-14.5', 'spread': '10.54', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14', 'description': 'Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of the individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores represent less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.'}, {'type': 'SECONDARY', 'title': 'CFB in the MDS-UPDRS Part I Total Score - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '9.9', 'spread': '6.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-4.7', 'spread': '6.54', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '6.05', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 7 (12 hours postdose), Day 14', 'description': 'Part I of the MDS-UPDRS assessed 13 nonmotor experiences of daily living categories. Part I total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.'}, {'type': 'SECONDARY', 'title': 'CFB in the MDS-UPDRS Part II Total Score - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '15.1', 'spread': '8.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.9', 'spread': '3.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.7', 'spread': '3.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.1', 'spread': '5.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.2', 'spread': '4.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.0', 'spread': '5.48', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.1', 'spread': '4.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.4', 'spread': '6.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '5.43', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-4.6', 'spread': '5.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.9', 'spread': '4.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.9', 'spread': '5.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 23 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '5.40', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '4.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '5.02', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14', 'description': 'Part II of the MDS-UPDRS assessed 13 categories of motor experiences of daily living: speech, salivation and drooling, chewing and swallowing, eating tasks, dressing, hygiene, handwriting, doing hobbies and other activities, turning in bed, tremor, getting out of bed, car, or deep chair, walking and balance, and freezing. The Part II total score was calculated as the sum of the individual item scores from these categories. The total score range for Part II is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.'}, {'type': 'SECONDARY', 'title': 'CFB in the MDS-UPDRS Part I-IV Total Score - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '84.6', 'spread': '24.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-30.0', 'spread': '17.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-24.1', 'spread': '20.75', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 7 (12 hours postdose), Day 14', 'description': 'The MDS-UPDRS assesses nonmotor experiences, motor experiences, motor skills, and motor complication categories. The MDS-UPDRS Part I-IV total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I-IV is 0 to 260. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With TEAEs - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}, {'id': 'OG001', 'title': 'Part B: Follow-up', 'description': 'Participants received antiparkinsonian agent(s) at normally prescribed dosing schedule for Days 8 to 14.'}], 'classes': [{'categories': [{'measurements': [{'value': '57.1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 to Day 14', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With TEAEs, Graded by Severity - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}, {'id': 'OG001', 'title': 'Part B: Follow-up', 'description': 'Participants received antiparkinsonian agent(s) at normally prescribed dosing schedule for Days 8 to 14.'}], 'classes': [{'title': 'Mild', 'categories': [{'measurements': [{'value': '42.9', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Moderate', 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Severe', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 to Day 14', 'description': 'Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with inability to perform normal activities). The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Basophils - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.074', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.089', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.058', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.061', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.055', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Basophils to Leukocytes Ratio (%) - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '1.0', 'spread': '0.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.47', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.73', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Eosinophils - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '0.12', 'spread': '0.058', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.065', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.083', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.114', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.058', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Eosinophils to Leukocytes Ratio (%) - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '2.0', 'spread': '1.04', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.7', 'spread': '1.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '0.95', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.93', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Erythrocytes - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '4.65', 'spread': '0.335', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.16', 'spread': '0.798', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.186', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.208', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.101', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^12 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Hematocrit - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '0.436', 'spread': '0.0357', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.023', 'spread': '0.0775', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.011', 'spread': '0.0182', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '0.006', 'spread': '0.0268', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.002', 'spread': '0.0119', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'L/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Hemoglobin - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '140.1', 'spread': '14.22', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '4.9', 'spread': '20.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.4', 'spread': '5.32', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '1.8', 'spread': '6.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.7', 'spread': '4.48', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Leukocytes - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '6.47', 'spread': '1.322', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.85', 'spread': '2.677', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.31', 'spread': '1.370', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.21', 'spread': '0.935', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.29', 'spread': '1.287', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Lymphocytes - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '1.68', 'spread': '0.549', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.44', 'spread': '0.857', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.26', 'spread': '0.386', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '0.18', 'spread': '0.283', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.11', 'spread': '0.373', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Lymphocytes to Leukocytes Ratio (%) - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '26.0', 'spread': '6.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '2.5', 'spread': '6.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '2.6', 'spread': '5.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '3.4', 'spread': '5.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.6', 'spread': '5.73', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Monocytes - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '0.40', 'spread': '0.096', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.194', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.083', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.133', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.110', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Monocytes to Leukocytes Ratio (%) - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '6.4', 'spread': '1.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.07', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Neutrophils - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '4.23', 'spread': '0.957', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.23', 'spread': '1.842', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.00', 'spread': '1.136', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.43', 'spread': '0.902', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.16', 'spread': '1.153', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Neutrophils to Leukocytes Ratio (%) - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '65.3', 'spread': '5.28', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-4.2', 'spread': '7.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-3.0', 'spread': '6.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '-4.4', 'spread': '6.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '6.69', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Platelets - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '189.2', 'spread': '37.72', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '24.1', 'spread': '67.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '5.9', 'spread': '13.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'categories': [{'measurements': [{'value': '0.8', 'spread': '20.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '5.3', 'spread': '19.58', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Reticulocytes - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '59.3', 'spread': '19.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '11.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.1', 'spread': '19.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '15.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.1', 'spread': '20.99', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': '10^9 cells/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Reticulocytes to Erythrocytes Ratio (%) - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.28', 'spread': '0.417', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.250', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.13', 'spread': '0.410', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.334', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.13', 'spread': '0.486', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Activated Partial Thromboplastin Time - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '25.05', 'groupId': 'OG000', 'lowerLimit': '22.0', 'upperLimit': '27.5'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.40', 'groupId': 'OG000', 'lowerLimit': '-2.1', 'upperLimit': '0.2'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'groupId': 'OG000', 'lowerLimit': '-1.7', 'upperLimit': '1.2'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.30', 'groupId': 'OG000', 'lowerLimit': '-1.6', 'upperLimit': '0.5'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.20', 'groupId': 'OG000', 'lowerLimit': '-1.4', 'upperLimit': '1.7'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'sec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Prothrombin International Normalized Ratio - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.98', 'spread': '0.043', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.045', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.051', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.041', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.036', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Prothrombin Time - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '10.60', 'groupId': 'OG000', 'lowerLimit': '9.6', 'upperLimit': '11.0'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.20', 'groupId': 'OG000', 'lowerLimit': '-0.8', 'upperLimit': '0.6'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'groupId': 'OG000', 'lowerLimit': '-0.5', 'upperLimit': '0.5'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'groupId': 'OG000', 'lowerLimit': '-0.4', 'upperLimit': '0.5'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.10', 'groupId': 'OG000', 'lowerLimit': '-0.3', 'upperLimit': '0.6'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'sec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Alanine Aminotransferase - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '10.0', 'spread': '6.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '3.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.6', 'spread': '5.42', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.9', 'spread': '3.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '3.70', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Albumin - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '44.2', 'spread': '2.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.40', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.16', 'spread': '1.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.86', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Alkaline Phosphatase - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '84.0', 'spread': '22.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '7.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '3.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.2', 'spread': '8.85', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '8.69', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Aspartate Aminotransferase - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '17.7', 'spread': '10.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '10.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '10.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '11.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '10.12', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Bicarbonate - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '24.6', 'spread': '1.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '1.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '2.06', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '2.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.77', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Bilirubin - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.306', 'spread': '2.4050', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.993', 'spread': '2.4320', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.795', 'spread': '2.0751', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.122', 'spread': '2.4611', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.366', 'spread': '3.0129', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Calcium - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.340', 'spread': '0.0796', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.006', 'spread': '0.0859', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.002', 'spread': '0.0599', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.023', 'spread': '0.0638', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.027', 'spread': '0.0709', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Chloride - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '102.1', 'spread': '2.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.53', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '2.10', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '2.36', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Creatinine - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '80.381', 'spread': '23.1753', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '11.345', 'spread': '17.8035', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.084', 'spread': '12.3449', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-2.968', 'spread': '8.0917', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.253', 'spread': '10.0339', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'umol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Lipase - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '37.2', 'spread': '16.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '15.4', 'spread': '9.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '19.4', 'spread': '16.88', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.3', 'spread': '6.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.6', 'spread': '9.30', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Magnesium - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.873', 'spread': '0.0489', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.014', 'spread': '0.0536', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.009', 'spread': '0.0401', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.018', 'spread': '0.0448', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.012', 'spread': '0.0591', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Phosphate - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.091', 'spread': '0.1489', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.161', 'spread': '0.1496', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.180', 'spread': '0.1386', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.042', 'spread': '0.1775', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.009', 'spread': '0.1939', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Potassium - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.57', 'spread': '0.292', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.319', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.264', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.295', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.268', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Protein - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '69.6', 'spread': '5.40', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '1.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '3.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '2.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '3.00', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Sodium - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '141.8', 'spread': '1.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '3.00', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Urate - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.291', 'spread': '0.0748', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.001', 'spread': '0.0252', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.001', 'spread': '0.0360', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.006', 'spread': '0.0254', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.007', 'spread': '0.0319', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Urea Nitrogen - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.993', 'spread': '1.7667', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.142', 'spread': '1.9554', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.275', 'spread': '1.7917', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.663', 'spread': '1.9345', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.153', 'spread': '1.2580', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Specific Gravity - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.018', 'spread': '0.0061', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.003', 'spread': '0.0038', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.001', 'spread': '0.0053', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.004', 'spread': '0.0077', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.0063', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in pH - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.11', 'spread': '0.924', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.18', 'spread': '1.103', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.32', 'spread': '1.085', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 8 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.39', 'spread': '0.984', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.820', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'pH', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.'}, {'type': 'SECONDARY', 'title': 'CFB in Temperature - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '36.56', 'spread': '0.306', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.199', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.316', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.19', 'spread': '0.316', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.23', 'spread': '0.370', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.15', 'spread': '0.375', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.310', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.380', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.485', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.327', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.15', 'spread': '0.282', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.386', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.451', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.408', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.358', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.336', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.418', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.423', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.562', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.512', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.240', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.266', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.289', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.363', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.477', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.348', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.352', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.415', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.291', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'degrees C', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Heart Rate - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '72.9', 'spread': '9.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '7.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '7.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.6', 'spread': '15.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '7.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '12.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '2.5', 'spread': '11.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.0', 'spread': '11.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.3', 'spread': '9.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '7.67', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '3.1', 'spread': '7.95', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '10.36', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '2.5', 'spread': '8.16', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.4', 'spread': '9.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '1.4', 'spread': '8.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '9.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '2.5', 'spread': '8.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.9', 'spread': '10.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '9.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-4.1', 'spread': '9.12', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '2.1', 'spread': '8.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.6', 'spread': '7.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '1.2', 'spread': '6.13', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '2.4', 'spread': '11.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.7', 'spread': '8.42', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.7', 'spread': '8.76', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.9', 'spread': '8.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.3', 'spread': '6.83', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-5.0', 'spread': '8.34', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'beats/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Respiratory Rate - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '15.6', 'spread': '1.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.8', 'spread': '1.31', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.9', 'spread': '2.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.9', 'spread': '2.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.8', 'spread': '1.58', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '2.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '2.36', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '1.4', 'spread': '1.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.45', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.4', 'spread': '1.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '2.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.78', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '2.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.6', 'spread': '1.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.7', 'spread': '2.40', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.90', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'breaths/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Supine Systolic Blood Pressure - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '131.7', 'spread': '16.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.7', 'spread': '9.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.4', 'spread': '7.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.3', 'spread': '13.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-3.3', 'spread': '18.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '2.9', 'spread': '14.61', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '16.11', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '6.1', 'spread': '18.57', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.2', 'spread': '12.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '10.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '13.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '22.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.4', 'spread': '16.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '14.22', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-4.3', 'spread': '14.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '1.2', 'spread': '18.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-5.7', 'spread': '14.67', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-4.0', 'spread': '15.54', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.6', 'spread': '18.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '2.3', 'spread': '11.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-10.9', 'spread': '17.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-6.5', 'spread': '18.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.8', 'spread': '18.48', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-4.1', 'spread': '15.90', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.7', 'spread': '12.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '2.4', 'spread': '12.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '2.5', 'spread': '11.94', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.2', 'spread': '13.98', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '3.4', 'spread': '15.55', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Standing Systolic Blood Pressure - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '127.8', 'spread': '14.89', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-2.9', 'spread': '10.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '8.41', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '7.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-3.4', 'spread': '15.96', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '14.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '1.7', 'spread': '15.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.8', 'spread': '13.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-4.2', 'spread': '11.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.8', 'spread': '11.56', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-4.4', 'spread': '11.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '17.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-4.5', 'spread': '12.68', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-4.1', 'spread': '18.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-5.5', 'spread': '11.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.8', 'spread': '13.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-7.5', 'spread': '8.26', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '12.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-5.6', 'spread': '14.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.3', 'spread': '10.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-9.4', 'spread': '8.80', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-6.6', 'spread': '11.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-4.7', 'spread': '10.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-8.6', 'spread': '11.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.2', 'spread': '9.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.4', 'spread': '10.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '3.5', 'spread': '13.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-7.5', 'spread': '12.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.7', 'spread': '14.50', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Supine Diastolic Blood Pressure - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '78.2', 'spread': '7.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.7', 'spread': '7.13', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '1.6', 'spread': '7.20', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '7.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '10.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.9', 'spread': '9.23', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '9.75', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '1.9', 'spread': '9.07', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '8.54', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.4', 'spread': '7.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.9', 'spread': '12.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '11.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '9.24', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.5', 'spread': '8.29', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.3', 'spread': '8.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '9.76', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '9.05', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.7', 'spread': '9.92', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '9.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '9.00', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '9.24', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.1', 'spread': '9.49', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '9.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '1.9', 'spread': '9.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '9.16', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.8', 'spread': '10.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.2', 'spread': '8.50', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '8.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.3', 'spread': '8.30', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Standing Diastolic Blood Pressure - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '81.9', 'spread': '6.99', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-2.0', 'spread': '6.04', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '6.32', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '7.17', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '7.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '5.11', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '7.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.9', 'spread': '8.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '8.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.4', 'spread': '9.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '7.44', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '7.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '7.53', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-4.1', 'spread': '9.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.9', 'spread': '8.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.8', 'spread': '9.18', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-5.5', 'spread': '8.93', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.4', 'spread': '7.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.1', 'spread': '8.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '10.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-4.0', 'spread': '7.74', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '8.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.0', 'spread': '7.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.1', 'spread': '8.27', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.7', 'spread': '9.21', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '8.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '8.14', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.7', 'spread': '8.59', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '9.21', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Pulse Oximetry - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '96.9', 'spread': '1.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.60', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '2.08', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.86', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.77', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.73', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 2 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.51', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.3', 'spread': '2.02', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.87', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '2.15', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.69', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.01', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.46', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 4 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.09', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.34', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '1.91', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.66', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.63', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.33', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 6 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.64', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.25', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.65', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 2 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.71', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.91', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in ECG Mean Heart Rate - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '71.4', 'spread': '10.24', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '5.55', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-6.6', 'spread': '7.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.2', 'spread': '6.19', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '5.03', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '9.88', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '2.2', 'spread': '6.28', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.8', 'spread': '7.82', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '9.39', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.2', 'spread': '6.81', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-0.7', 'spread': '6.97', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '1.4', 'spread': '6.35', 'groupId': 'OG000'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-6.1', 'spread': '8.57', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'beats/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Aggregate PR Interval - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '174.0', 'groupId': 'OG000', 'lowerLimit': '141', 'upperLimit': '203'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000', 'lowerLimit': '-20', 'upperLimit': '96'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-24', 'upperLimit': '17'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-29', 'upperLimit': '8'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-33', 'upperLimit': '8'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '3.5', 'groupId': 'OG000', 'lowerLimit': '-27', 'upperLimit': '20'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000', 'lowerLimit': '-28', 'upperLimit': '46'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-19', 'upperLimit': '12'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-22', 'upperLimit': '22'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-17', 'upperLimit': '18'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-36', 'upperLimit': '10'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-26', 'upperLimit': '27'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '-2.5', 'groupId': 'OG000', 'lowerLimit': '-31', 'upperLimit': '7'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Aggregate RR Interval - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '823.0', 'groupId': 'OG000', 'lowerLimit': '683', 'upperLimit': '1239'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-19.0', 'groupId': 'OG000', 'lowerLimit': '-93', 'upperLimit': '142'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '67.5', 'groupId': 'OG000', 'lowerLimit': '-68', 'upperLimit': '366'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-32.5', 'groupId': 'OG000', 'lowerLimit': '-85', 'upperLimit': '141'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-10.0', 'groupId': 'OG000', 'lowerLimit': '-140', 'upperLimit': '143'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '7.0', 'groupId': 'OG000', 'lowerLimit': '-164', 'upperLimit': '231'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-23.5', 'groupId': 'OG000', 'lowerLimit': '-132', 'upperLimit': '99'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-24.5', 'groupId': 'OG000', 'lowerLimit': '-148', 'upperLimit': '96'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000', 'lowerLimit': '-185', 'upperLimit': '304'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-16.0', 'groupId': 'OG000', 'lowerLimit': '-80', 'upperLimit': '212'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-26.0', 'groupId': 'OG000', 'lowerLimit': '-76', 'upperLimit': '180'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '16.5', 'groupId': 'OG000', 'lowerLimit': '-148', 'upperLimit': '74'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '66.0', 'groupId': 'OG000', 'lowerLimit': '-76', 'upperLimit': '397'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Aggregate QT Interval - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '374.0', 'groupId': 'OG000', 'lowerLimit': '361', 'upperLimit': '442'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '3.5', 'groupId': 'OG000', 'lowerLimit': '-41', 'upperLimit': '36'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '10.0', 'groupId': 'OG000', 'lowerLimit': '-20', 'upperLimit': '70'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-21', 'upperLimit': '32'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '3.5', 'groupId': 'OG000', 'lowerLimit': '-34', 'upperLimit': '31'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-52', 'upperLimit': '31'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-35', 'upperLimit': '17'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-5.5', 'groupId': 'OG000', 'lowerLimit': '-37', 'upperLimit': '25'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '11.0', 'groupId': 'OG000', 'lowerLimit': '-45', 'upperLimit': '41'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-5.0', 'groupId': 'OG000', 'lowerLimit': '-23', 'upperLimit': '21'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '3.5', 'groupId': 'OG000', 'lowerLimit': '-32', 'upperLimit': '32'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000', 'lowerLimit': '-30', 'upperLimit': '21'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '14.0', 'groupId': 'OG000', 'lowerLimit': '-19', 'upperLimit': '57'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Aggregate QRS Duration - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '99.5', 'groupId': 'OG000', 'lowerLimit': '76', 'upperLimit': '153'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-9', 'upperLimit': '12'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-8', 'upperLimit': '16'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-11', 'upperLimit': '9'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-12', 'upperLimit': '10'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-0.5', 'groupId': 'OG000', 'lowerLimit': '-14', 'upperLimit': '6'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-10', 'upperLimit': '16'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000', 'lowerLimit': '-5', 'upperLimit': '11'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-3.5', 'groupId': 'OG000', 'lowerLimit': '-12', 'upperLimit': '6'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-0.5', 'groupId': 'OG000', 'lowerLimit': '-5', 'upperLimit': '238'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-10', 'upperLimit': '6'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-11', 'upperLimit': '6'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '-11', 'upperLimit': '11'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': 'CFB in Aggregate QTcF Interval - Part B', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '407.0', 'groupId': 'OG000', 'lowerLimit': '384', 'upperLimit': '432'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '3.0', 'groupId': 'OG000', 'lowerLimit': '-35', 'upperLimit': '54'}]}]}, {'title': 'CFB at Dose 1 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-2.5', 'groupId': 'OG000', 'lowerLimit': '-34', 'upperLimit': '60'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-11', 'upperLimit': '28'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '-18', 'upperLimit': '29'}]}]}, {'title': 'CFB at Dose 3 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '-1.5', 'groupId': 'OG000', 'lowerLimit': '-37', 'upperLimit': '12'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000', 'lowerLimit': '-19', 'upperLimit': '19'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '-19', 'upperLimit': '22'}]}]}, {'title': 'CFB at Dose 5 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '5.5', 'groupId': 'OG000', 'lowerLimit': '-27', 'upperLimit': '17'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): Predose', 'categories': [{'measurements': [{'value': '-1.0', 'groupId': 'OG000', 'lowerLimit': '-16', 'upperLimit': '29'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 1 Hour Postdose', 'categories': [{'measurements': [{'value': '-2.0', 'groupId': 'OG000', 'lowerLimit': '-25', 'upperLimit': '20'}]}]}, {'title': 'CFB at Dose 7 (SAGE-217): 12 Hours Postdose', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '-11', 'upperLimit': '17'}]}]}, {'title': 'CFB at Day 14 (Follow-up)', 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '-10', 'upperLimit': '21'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'msec', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants With a Response of 'Yes' to Any C-SSRS Suicidal Ideation or Suicidal Behavior Item - Part B", 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'classes': [{'title': 'Suicidal Ideation: Wish to be Dead: Pre-treatment', 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}]}]}, {'title': 'Suicidal Ideation: Wish to be Dead: Post-treatment', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Suicidal Behavior: Pre-treatment', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Suicidal Behavior: Post-treatment', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 1 to Day 14', 'description': 'The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included "yes" or "no"\' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part B of the study.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who were administered study drug.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}, {'id': 'FG001', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '14'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '14'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'Participants were enrolled at 9 sites in the United States and took part in the study which ran from 30 November 2016 to 11 September 2017.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '29', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.'}, {'id': 'BG001', 'title': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '63.9', 'spread': '6.59', 'groupId': 'BG000'}, {'value': '65.1', 'spread': '7.76', 'groupId': 'BG001'}, {'value': '64.5', 'spread': '7.17', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '26', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The safety population included all participants who were administered study drug \\[SAGE-217 or levodopa (Part A); or SAGE-217 or antiparkinsonian agent(s) (Part B)\\].'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-06-08', 'size': 6637928, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_001.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-09-17T20:30', 'hasProtocol': True}, {'date': '2017-08-02', 'size': 11235706, 'label': 'Statistical Analysis Plan: Version 2', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_000.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-09-17T19:41', 'hasProtocol': False}, {'date': '2017-02-06', 'size': 9738893, 'label': 'Statistical Analysis Plan: Version 1', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_002.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-09-17T20:39', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 29}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-11-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-11', 'dispFirstSubmitDate': '2018-09-17', 'completionDateStruct': {'date': '2017-09-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-27', 'studyFirstSubmitDate': '2016-11-28', 'dispFirstSubmitQcDate': '2018-10-09', 'resultsFirstSubmitDate': '2020-09-17', 'studyFirstSubmitQcDate': '2016-12-19', 'dispFirstPostDateStruct': {'date': '2018-10-11', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2023-11-29', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-10-29', 'studyFirstPostDateStruct': {'date': '2016-12-22', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2020-11-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-09-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'Percentage of Participants With TEAEs, Graded by Severity - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with an inability to perform normal activities). The analysis was performed in participants included in Part A of the study.'}, {'measure': 'Change From Baseline (CFB) in Basophils - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Basophils to Leukocytes Ratio [Percentage (%)] - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as International System (SI) unit, percentage (%).'}, {'measure': 'CFB in Eosinophils - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Eosinophils to Leukocytes Ratio (%) - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Erythrocytes - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Hematocrit - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Hemoglobin - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Leukocytes - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Lymphocytes - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Lymphocytes to Leukocytes Ratio (%) - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Monocytes - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Monocytes to Leukocytes Ratio (%) - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Neutrophils- Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Neutrophils to Leukocytes Ratio (%) - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Platelets - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Reticulocytes - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Reticulocytes to Erythrocytes Ratio (%) - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Activated Partial Thromboplastin Time - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Prothrombin International Normalized Ratio - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Prothrombin Time - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Alanine Aminotransferase - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Albumin - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Alkaline Phosphatase - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Aspartate Aminotransferase - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Bicarbonate - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Bilirubin - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Calcium - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Chloride - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Creatinine - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Lipase - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Magnesium - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Phosphate - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Potassium - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Protein - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Sodium - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Urate - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Urea Nitrogen - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Specific Gravity - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and potential of hydrogen (pH). Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in pH - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Temperature - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Heart Rate - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Respiratory Rate - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Supine Systolic Blood Pressure - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Standing Systolic Blood Pressure - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Supine Diastolic Blood Pressure - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Standing Diastolic Blood Pressure - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Pulse Oximetry- Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Electrocardiogram (ECG) Mean Heart Rate - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Aggregate PR Interval - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Aggregate RR Interval - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Aggregate QT Interval - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Aggregate QRS Duration - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Aggregate QTcF Interval - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in Stanford Sleepiness Scale (SSS) Score - Part A', 'timeFrame': 'Day 1 to Day 14', 'description': "The SSS was a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of one to seven, where the lowest score of 'one' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of 'seven' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. A negative change from baseline indicated less sleepiness. A positive change from baseline indicated more sleepiness. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study."}, {'measure': "Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item - Part A", 'timeFrame': 'Day 1 to Day 14', 'description': 'The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included "yes" or "no"\' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part A of the study.'}, {'measure': "CFB in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II/III Score - Part B", 'timeFrame': 'Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14', 'description': 'The modified MDS-UPDRS included 4 scales, with various subscales. Each item was rated from 0 (normal) to 4 (severe). The scales were Part I: nonmotor experiences of daily living (13 items); Part II: motor experiences of daily living (13 items); Part III: motor examination (33 scores based on 18 items \\[several with right, left or other body distribution scores\\]); and Part IV: motor complications (6 items). The Part II/III tremor score was calculated as the sum of 5 individual tremor item scores from Part II and Part III. The total score range for Part II/III is 0 to 44. Lower scores represent less symptom severity and higher scores represent more symptom severity. Baseline is the last measurement taken before the first dose of study drug. A negative change from baseline indicates an improvement in symptom severity. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}], 'secondaryOutcomes': [{'measure': 'MDS-UPDRS Part III Total Score - Part A', 'timeFrame': 'Days 1 to 7 (2, 4, 8, and 12 hours postdose), Day 8 and Day 14', 'description': 'Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores indicate less symptom severity. The analysis was performed in participants included in Part A of the study.'}, {'measure': 'CFB in the MDS-UPDRS Part III Total Score - Part B', 'timeFrame': 'Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14', 'description': 'Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of the individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores represent less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in the MDS-UPDRS Part I Total Score - Part B', 'timeFrame': 'Baseline, Day 7 (12 hours postdose), Day 14', 'description': 'Part I of the MDS-UPDRS assessed 13 nonmotor experiences of daily living categories. Part I total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in the MDS-UPDRS Part II Total Score - Part B', 'timeFrame': 'Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14', 'description': 'Part II of the MDS-UPDRS assessed 13 categories of motor experiences of daily living: speech, salivation and drooling, chewing and swallowing, eating tasks, dressing, hygiene, handwriting, doing hobbies and other activities, turning in bed, tremor, getting out of bed, car, or deep chair, walking and balance, and freezing. The Part II total score was calculated as the sum of the individual item scores from these categories. The total score range for Part II is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in the MDS-UPDRS Part I-IV Total Score - Part B', 'timeFrame': 'Baseline, Day 7 (12 hours postdose), Day 14', 'description': 'The MDS-UPDRS assesses nonmotor experiences, motor experiences, motor skills, and motor complication categories. The MDS-UPDRS Part I-IV total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I-IV is 0 to 260. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'Percentage of Participants With TEAEs - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'Percentage of Participants With TEAEs, Graded by Severity - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with inability to perform normal activities). The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Basophils - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Basophils to Leukocytes Ratio (%) - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Eosinophils - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Eosinophils to Leukocytes Ratio (%) - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Erythrocytes - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Hematocrit - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Hemoglobin - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Leukocytes - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Lymphocytes - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Lymphocytes to Leukocytes Ratio (%) - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Monocytes - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Monocytes to Leukocytes Ratio (%) - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Neutrophils - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Neutrophils to Leukocytes Ratio (%) - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Platelets - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Reticulocytes - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Reticulocytes to Erythrocytes Ratio (%) - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).'}, {'measure': 'CFB in Activated Partial Thromboplastin Time - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Prothrombin International Normalized Ratio - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Prothrombin Time - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Alanine Aminotransferase - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Albumin - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Alkaline Phosphatase - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Aspartate Aminotransferase - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Bicarbonate - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Bilirubin - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Calcium - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Chloride - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Creatinine - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Lipase - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Magnesium - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Phosphate - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Potassium - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Protein - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Sodium - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Urate - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Urea Nitrogen - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Specific Gravity - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in pH - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Temperature - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Heart Rate - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Respiratory Rate - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Supine Systolic Blood Pressure - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Standing Systolic Blood Pressure - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Supine Diastolic Blood Pressure - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Standing Diastolic Blood Pressure - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Pulse Oximetry - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in ECG Mean Heart Rate - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Aggregate PR Interval - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Aggregate RR Interval - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Aggregate QT Interval - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Aggregate QRS Duration - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': 'CFB in Aggregate QTcF Interval - Part B', 'timeFrame': 'Day 1 to Day 14', 'description': 'ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.'}, {'measure': "Percentage of Participants With a Response of 'Yes' to Any C-SSRS Suicidal Ideation or Suicidal Behavior Item - Part B", 'timeFrame': 'Day 1 to Day 14', 'description': 'The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included "yes" or "no"\' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part B of the study.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ["Parkinson's"], 'conditions': ['Parkinson Disease']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.sagerx.com', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': "This study assesses the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in 29 participants with moderate to severe Parkinson's Disease.", 'detailedDescription': 'Part A of the study is an open-label design with dosing of Levodopa for 3 days followed by SAGE-217 for 4 days.\n\nPart B of the study is an open-label design with evening dosing of SAGE-217 for 7 days as an adjunct to antiparkinsonian agent(s).\n\nThis study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Participant has a diagnosis of idiopathic Parkinson\'s Disease (Hoehn and Yahr Stage 2 or Stage 3) with a duration of less than 7 years prior to screening \\[Part A\\]\n* Participant has a diagnosis of idiopathic Parkinson\'s Disease (Hoehn and Yahr Stage 1-4, assessed during the "on" period) \\[Part B\\]\n* Participant is on a stable dose (at least 1 month prior to baseline visit) of an antiparkinsonian agent and is willing to remain on this dose for the duration of the study\n\nExclusion Criteria:\n\n* Participant has early (Hoehn and Yahr Stage 1) or advanced (Hoehn and Yahr Stage 4 or Stage 5) Parkinson\'s Disease \\[Part A\\]\n* Participant has advanced (Hoehn and Yahr Stage 5) Parkinson\'s Disease \\[Part B\\]\n* Participant with presence of drug-induced parkinsonism, metabolic identified neurogenetic disorders, encephalitis, or other atypical Parkinsonian syndromes\n* Participant with medical history of electroconvulsive therapy or stereotaxic brain surgery for Parkinson\'s Disease\n* Participant with medical history of suicide attempt within 2 years of screening or current suicidal ideation\n* Participant with medical history of impulse control disorder'}, 'identificationModule': {'nctId': 'NCT03000569', 'briefTitle': "A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease", 'organization': {'class': 'INDUSTRY', 'fullName': 'Biogen'}, 'officialTitle': "A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease", 'orgStudyIdInfo': {'id': '217-PRK-201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'description': 'Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.', 'interventionNames': ['Drug: SAGE-217', 'Drug: Levodopa']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: Antiparkinsonian Agent(s) + SAGE-217', 'description': 'Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.', 'interventionNames': ['Drug: SAGE-217', 'Drug: Antiparkinsonian Agent(s)']}], 'interventions': [{'name': 'SAGE-217', 'type': 'DRUG', 'armGroupLabels': ['Part A: Antiparkinsonian Agent(s) Followed by SAGE-217', 'Part B: Antiparkinsonian Agent(s) + SAGE-217']}, {'name': 'Levodopa', 'type': 'DRUG', 'description': 'Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).', 'armGroupLabels': ['Part A: Antiparkinsonian Agent(s) Followed by SAGE-217']}, {'name': 'Antiparkinsonian Agent(s)', 'type': 'DRUG', 'description': 'Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.', 'armGroupLabels': ['Part B: Antiparkinsonian Agent(s) + SAGE-217']}]}, 'contactsLocationsModule': {'locations': [{'zip': '91402', 'city': 'Panorama City', 'state': 'California', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 34.22473, 'lon': -118.44981}}, {'zip': '32216', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33135', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33143', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32806', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32789', 'city': 'Winter Park', 'state': 'Florida', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 28.6, 'lon': -81.33924}}, {'zip': '30331', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '48334', 'city': 'Farmington Hills', 'state': 'Michigan', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 42.48531, 'lon': -83.37716}}, {'zip': '08009', 'city': 'Berlin', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 39.79123, 'lon': -74.92905}}, {'zip': '77058', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '84058', 'city': 'Orem', 'state': 'Utah', 'country': 'United States', 'facility': 'Sage Investigational Site', 'geoPoint': {'lat': 40.2969, 'lon': -111.69465}}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/', 'ipdSharing': 'YES', 'description': "In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Biogen', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}